Swedish Orphan Biovitrum (Sobi) is dedicated to addressing the unmet medical needs of patients with rare diseases through innovative research and development. The company focuses on creating new therapies primarily in the fields of Haematology and Immunology, where they aim to bring new treatments to market and expand existing products into new indications and regions. Sobi's commitment to patient access is evident in their structured approach to navigating the complexities of drug development, which includes managing long timelines and inherent risks associated with bringing new therapies to patients.

Sobi's research and development pipeline emphasizes the importance of real-world evidence and late-stage research, particularly for conditions such as haemophilia, immune thrombocytopenia (ITP), and various immunological disorders. The company also engages in investigator-sponsored studies and managed access programs to ensure that patients have access to their innovative treatments. By focusing on these areas, Sobi aims to transform the lives of individuals affected by rare and debilitating diseases, reinforcing their commitment to patient-centric care and sustainable progress in healthcare.

Sweden

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2022, our revenue amounted to SEK 18.8 billion. 

Swedish Orphan Biovitrum

Company Details